Sol-Gel Technologies SG&A Expenses 2016-2023 | SLGL
Sol-Gel Technologies sg&a expenses from 2016 to 2023. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
Sol-Gel Technologies Annual SG&A Expenses
(Millions of US $) |
| 2023 |
$7 |
| 2022 |
$7 |
| 2021 |
$8 |
| 2020 |
$11 |
| 2019 |
$8 |
| 2018 |
$6 |
| 2017 |
$6 |
| 2016 |
$4 |
| 2015 |
$2 |
Sol-Gel Technologies Quarterly SG&A Expenses
(Millions of US $) |
| 2023-12-31 |
$2 |
| 2023-09-30 |
$2 |
| 2023-06-30 |
$2 |
| 2023-03-31 |
$2 |
| 2022-12-31 |
$2 |
| 2022-09-30 |
$2 |
| 2022-06-30 |
$2 |
| 2022-03-31 |
$2 |
| 2021-12-31 |
$2 |
| 2021-09-30 |
$2 |
| 2021-06-30 |
$2 |
| 2021-03-31 |
$2 |
| 2020-12-31 |
$3 |
| 2020-09-30 |
$3 |
| 2020-06-30 |
$2 |
| 2020-03-31 |
$3 |
| 2019-12-31 |
$2 |
| 2019-09-30 |
$2 |
| 2019-06-30 |
$2 |
| 2019-03-31 |
$2 |
| 2018-12-31 |
$2 |
| 2018-09-30 |
$1 |
| 2018-06-30 |
$2 |
| 2018-03-31 |
$1 |
| 2017-12-31 |
|
| 2017-09-30 |
|
| 2017-06-30 |
$2 |
| 2016-12-31 |
|
| 2015-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.019B |
$0.002B |
|
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
|
